COST

958.07

-1.14%↓

PG

158.49

-0.09%↓

KO

70.07

-0.72%↓

PM

171.29

-1.72%↓

PEP

149.48

+0.37%↑

COST

958.07

-1.14%↓

PG

158.49

-0.09%↓

KO

70.07

-0.72%↓

PM

171.29

-1.72%↓

PEP

149.48

+0.37%↑

COST

958.07

-1.14%↓

PG

158.49

-0.09%↓

KO

70.07

-0.72%↓

PM

171.29

-1.72%↓

PEP

149.48

+0.37%↑

COST

958.07

-1.14%↓

PG

158.49

-0.09%↓

KO

70.07

-0.72%↓

PM

171.29

-1.72%↓

PEP

149.48

+0.37%↑

COST

958.07

-1.14%↓

PG

158.49

-0.09%↓

KO

70.07

-0.72%↓

PM

171.29

-1.72%↓

PEP

149.48

+0.37%↑

Search

Lifecore Biomedical Inc

Slēgts

SektorsPatēriņa aizsardzības

7.57 5.43

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

7.08

Max

7.62

Galvenie mērījumi

By Trading Economics

Ienākumi

14M

-1.1M

Pārdošana

1.3M

36M

P/E

Sektora vidējais

201.137

26.65

EPS

-0.253

Peļņas marža

-3.147

Darbinieki

406

EBITDA

-5.5M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+38.5% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 3. okt.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

8.9M

235M

Iepriekšējā atvēršanas cena

2.14

Iepriekšējā slēgšanas cena

7.57

Ziņu noskaņojums

By Acuity

13%

87%

6 / 150 Rangs Consumer defensive

Lifecore Biomedical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 22. aug. 23:09 UTC

Iegādes, apvienošanās, pārņemšana

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 4th Update

2025. g. 22. aug. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Agreement Could Also Lead to Deeper Collaboration Between CSX, BNSF

2025. g. 22. aug. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Some Analysts Say Agreement Suggests Lack of Confidence in Merger

2025. g. 22. aug. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

CSX, BNSF Intermodal Pact Draws Competing Views on Merger Possibility

2025. g. 22. aug. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

CSX, BNSF Pact Sparks Debate on Whether Another Rail Merger Is Approaching -- Analysis

2025. g. 22. aug. 22:02 UTC

Iegādes, apvienošanās, pārņemšana

Pact Could Show Regulators That Transcontinental Service Can Come Without Merger

2025. g. 22. aug. 21:23 UTC

Tirgus saruna

Moody's Lowers Outlook on Austria to Negative From Stable -- Market Talk

2025. g. 22. aug. 21:18 UTC

Tirgus saruna

US Economic Growth Seen Slowing This Year -- Market Talk

2025. g. 22. aug. 21:18 UTC

Iegādes, apvienošanās, pārņemšana

U.S. Takes 10% Stake in Intel -- Barrons.com

2025. g. 22. aug. 21:03 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 22. aug. 21:03 UTC

Tirgus saruna

Mexican Stocks Close At Record High -- Market Talk

2025. g. 22. aug. 20:58 UTC

Tirgus saruna

US General Government Deficit Expected to Rise in 2026, 2027 -- Market Talk

2025. g. 22. aug. 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Intel: Government's Investment in Intel Will Be a Passive Ownership, With No Bd Representation or Other Governance or Info Rights >INTC

2025. g. 22. aug. 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Intel: Government Also Agrees to Vote With the Company's Bd of Directors on Matters Requiring Shareholder Approval, With Limited Exceptions >INTC

2025. g. 22. aug. 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Intel: Government Equity Stake Will Be Funded by Remaining $5.7B in Grants Previously Awarded, But Not Yet Paid, Under U.S. CHIPS and Science Act and $3.2B Awarded as Part of Secure Enclave Program >INTC

2025. g. 22. aug. 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Intel: Government Agrees to Purchase 433.3M Primary Shrs of Intel Common Stk at a Price of $20.47 per Shr, Equivalent to a 9.9% Stake in Co >INTC

2025. g. 22. aug. 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Intel: U.S. Government to Make $8.9B Investment in Intel Common Stk as Co Builds Upon Its More Than $100B Expansion of Resilient Semiconductor Supply Chain >INTC

2025. g. 22. aug. 20:57 UTC

Iegādes, apvienošanās, pārņemšana

Intel: Intel and Trump Admin Reach Historic Agreement to Accelerate Amer Technology and Manufacturing Leadership

2025. g. 22. aug. 20:56 UTC

Peļņas

These Stocks Moved the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

2025. g. 22. aug. 20:55 UTC

Peļņas

These Stocks Are Moving the Most Today: Nvidia, Builders FirstSource, Zoom, Intuit, Workday, BJ's, Ubiquiti, and More -- Barrons.com

2025. g. 22. aug. 20:50 UTC

Tirgus saruna
Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 22. aug. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2025. g. 22. aug. 20:41 UTC

Iegādes, apvienošanās, pārņemšana

U.S. Has 10% Stake in Intel, Lutnick Says -- Barrons.com

2025. g. 22. aug. 20:24 UTC

Iegādes, apvienošanās, pārņemšana

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 3rd Update

2025. g. 22. aug. 20:16 UTC

Iegādes, apvienošanās, pārņemšana

CSX and Warren Buffett's BNSF Made News. Why Investors Are Disappointed. -- Barrons.com

2025. g. 22. aug. 19:19 UTC

Tirgus saruna

Boeing to Restart Talks With Defense Workers' Union Monday -- Market Talk

2025. g. 22. aug. 19:10 UTC

Tirgus saruna

Oil Futures Gain as Russia-Ukraine Peace Seems Distant -- Market Talk

2025. g. 22. aug. 19:06 UTC

Tirgus saruna

U.S. Natural Gas Extends Losses as Summer Nears an End -- Market Talk

2025. g. 22. aug. 19:03 UTC

Tirgus saruna

Lower Borrowing Rates Elusive Even if Fed Cuts -- Market Talk

2025. g. 22. aug. 18:52 UTC

Iegādes, apvienošanās, pārņemšana

Trump Says U.S. Will Take Nearly 10% Equity Stake in Intel -- 2nd Update

Salīdzinājums

Cenas izmaiņa

Lifecore Biomedical Inc Prognoze

Cenas mērķis

By TipRanks

38.5% augšup

Prognoze 12 mēnešiem

Vidējais 10 USD  38.5%

Augstākais 10 USD

Zemākais 10 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

2

Pirkt

1

Turēt

0

Pārdot

Noskaņojums

By Acuity

6 / 150 Rangs Patēriņa aizsardzības

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Vidējais

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.